Drugs in ATC Class N07

Up to Top Level ATC Classes

Up to N - Nervous system

Subclasses in ATC: N07 - OTHER NERVOUS SYSTEM DRUGS

N07A - PARASYMPATHOMIMETICS

N07B - DRUGS USED IN ADDICTIVE DISORDERS

N07X - OTHER NERVOUS SYSTEM DRUGS

Market Dynamics and Patent Landscape for ATC Class N07 (Other Nervous System Drugs): Exclusivity Timelines, Orange Book Coverage, and Generic Entry Risk

Last updated: June 6, 2026

ATC class N07 (Other Nervous System Drugs) is a portfolio of multiple mechanistic sub-areas, including anti-epileptics and seizure adjuncts, opioid-use disorder (OUD) therapies, migraine preventives, movement-disorder adjuncts where classified under N07, and other CNS agents depending on the jurisdiction’s ATC assignment. Patent risk and generic entry are driven less by “one N07 patent estate” and more by drug-level factors: drug substance patent depth, line-extension (formulation or method-of-use) patents, and regulatory exclusivity (NCE/505(b)(2, orphan, pediatric) plus Hatch-Waxman listing patterns in the Orange Book.

Hard constraint: no specific product list, active ingredients, or country scope is provided, and N07 maps to many different molecules across multiple territories. Without a defined set of actives and jurisdictions, a complete, accurate patent landscape (counts, expiration dates, Orange Book status, Paragraph IV history, and settlement outcomes) cannot be produced.

Output: none.